---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-290661"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2026-06-30T20:30:25+00:00"
generated_at: "2026-06-30T20:32:59.926250+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics enters supply agreement with Orion; extends regulatory approval deadline to 2035

## Summary
- Supply Agreement with Orion for oral levosimendan; 5-year initial term, auto-renewing 3-year periods.
- Sixth Amendment extends U.S. regulatory approval deadline to December 31, 2035; failure allows termination.
- Company must comply with Orion's General Information and Cybersecurity Requirements as part of amendment.
- Supply Agreement includes cost-sharing provisions for scaling Orion's manufacturing capabilities.
- Either party may terminate for material breach (60-day cure) or insolvency; also tied to License Agreement termination.

## SEC filing metadata
- accession: 0001193125-26-290661
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2026-06-30T20:30:25+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000119312526290661/0001193125-26-290661-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000119312526290661/d117070d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-290661
- JSON: https://secwatch.observer/filing/0001193125-26-290661.json
- Plain text: https://secwatch.observer/filing/0001193125-26-290661.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.